Position in EXEL
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$311,035
-$12,514 QoQ
Shares Held
7,252
-1.8% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JOURNEY STRATEGIC WEALTH LLC holds $11,646,586 across 14 Biotechnology names. EXEL ranks #5 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
12,829 | $6,715,596 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,572 | $1,214,585 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,143 | $956,931 | |
| 4 | ZYME |
Zymeworks Inc.
|
29,050 | $727,410 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
7,252 | $311,035 | |
| 6 | INCY |
Incyte Corp
|
3,272 | $307,958 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
4,546 | $285,033 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
1,305 | $246,708 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $311,035 | 7,252 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $323,549 | 7,382 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $253,456 | 6,137 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $280,831 | 6,371 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||